The ubiquitin pathway: An emerging drug target in cancer therapy

European Journal of Pharmacology

Volumn 625, Issue 1-3, 2009, Pages 199-205

  Ande, Sudharsana Rao ^a   Chen, Junjie ^b   Maddika, Subbareddy ^b,c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INSTITUTE OF LIFE SCIENCES   (India)

Author keywords

Cancer therapy; Deubiquitinases; E3 ligase; Inhibitors; Proteosome; Ubiquitin

Indexed keywords

4[4 (5 NITRO FURAN 2 YLMETHYLENE) 3,5 DIOXO PYRAZOLIDIN 1 YL]BENZOIC ACID ETHYL ESTER; AEG 35156; ANTINEOPLASTIC AGENT; ARGYRIN A; BORTEZOMIB; CARFILZOMIB; CEP 18770; CYCLOPENTENONE; GEMCITABINE; INHIBITOR OF APOPTOSIS PROTEIN; LIGASE INHIBITOR; N [6 [(ANILINOCARBONYL)AMINO] 5 [(ANILINOCARBONYL)AMINO]HEXYL] N METHYL N' PHENYLUREA; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN MDM2; PROTEOLYSIS TARGETING CHIMERIC MOLECULE; PYR 41; SALINOSPORAMIDE A; SCF BETA TRCP LIGASE COMPLEX; SCF SKP2 LIGASE COMPLEX; SEMPERVIRINE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E1; UBIQUITIN PROTEIN LIGASE E3; UBISTATIN; UNCLASSIFIED DRUG; VCB CUL2 VHL LIGASE COMPLEX;

APOPTOSIS; BREAST CANCER; CANCER THERAPY; CELL PROLIFERATION; CLINICAL TRIAL; COMBINATORIAL CHEMISTRY; DRUG POTENTIATION; DRUG TARGETING; ENDOCYTOSIS; HIGH THROUGHPUT SCREENING; HUMAN; LUNG NON SMALL CELL CANCER; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TRANSCRIPTION REGULATION; UBIQUITINATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 71749086813     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.08.042     Document Type: Review

References (61)

1. Arnt C.R., Chiorean M.V., Heldebrant M.P., Gores G.J., and Kaufmann S.H. Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J. Biol. Chem. 277 (2002) 44236-44243
2. Bernassola F., Karin M., Ciechanover A., and Melino G. The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell 14 (2008) 10-21
3. Bond G.L., Hu W., and Levine A.J. MDM2 is a central node in the p53 pathway: 12 years and counting. Current Cancer Drug Targets 5 (2005) 3-8
4. Brown S., Niimi A., and Lehmann A.R. Ubiquitination and deubiquitination of PCNA in response to stalling of the replication fork. Cell Cycle (Georgetown, Tex.) 8 (2009) 689-692
5. Burger A.M., and Seth A.K. The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur. J. Cancer 40 (2004) 2217-2229
6. Chauhan D., Catley L., Li G., Podar K., Hideshima T., Velankar M., Mitsiades C., Mitsiades N., Yasui H., Letai A., Ovaa H., Berkers C., Nicholson B., Chao T.H., Neuteboom S.T., Richardson P., Palladino M.A., and Anderson K.C. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8 (2005) 407-419
7. Ciechanover A., and Schwartz A.L. The ubiquitin system: pathogenesis of human diseases and drug targeting. Biochim. Biophys. Acta 1695 (2004) 3-17
8. Ciechanover A., Elias S., Heller H., Ferber S., and Hershko A. Characterization of the heat-stable polypeptide of the ATP-dependent proteolytic system from reticulocytes. J. Biol. Chem. 255 (1980) 7525-7528
9. Ciechanover A., Heller H., Elias S., Haas A.L., and Hershko A. ATP-dependent conjugation of reticulocyte proteins with the polypeptide required for protein degradation. Proc. Natl Acad. Sci. USA 77 (1980) 1365-1368
10. Cummins J.M., Rago C., Kohli M., Kinzler K.W., Lengauer C., and Vogelstein B. Tumour suppression: disruption of HAUSP gene stabilizes p53. Nature 428 (2004) 1 p following 486
11. Ding K., Lu Y., Nikolovska-Coleska Z., Wang G., Qiu S., Shangary S., Gao W., Qin D., Stuckey J., Krajewski K., Roller P.P., and Wang S. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J. Med. Chem. 49 (2006) 3432-3435
12. Glickman M.H., and Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82 (2002) 373-428
13. Graner E., Tang D., Rossi S., Baron A., Migita T., Weinstein L.J., Lechpammer M., Huesken D., Zimmermann J., Signoretti S., and Loda M. The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell 5 (2004) 253-261
14. Hershko A., and Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 67 (1998) 425-479
15. Hershko A., Heller H., Elias S., and Ciechanover A. Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. J. Biol. Chem. 258 (1983) 8206-8214
16. Hjerpe R., and Rodriguez M.S. Alternative UPS drug targets upstream the 26S proteasome. Int. J. Biochem. Cell Biol. 40 (2008) 1126-1140
17. Hoeller D., and Dikic I. Targeting the ubiquitin system in cancer therapy. Nature 458 (2009) 438-444
18. Issaeva N., Bozko P., Enge M., Protopopova M., Verhoef L.G., Masucci M., Pramanik A., and Selivanova G. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 10 (2004) 1321-1328
19. Jones R.J., Chen Q., Voorhees P.M., Young K.H., Bruey-Sedano N., Yang D., and Orlowski R.Z. Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage-independent p53 phosphorylation in mantle cell lymphoma. Clin. Cancer Res. 14 (2008) 5416-5425
20. Karikari C.A., Roy I., Tryggestad E., Feldmann G., Pinilla C., Welsh K., Reed J.C., Armour E.P., Wong J., Herman J., Rakheja D., and Maitra A. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein. Mol. Cancer Ther. 6 (2007) 957-966
21. Kim H., Chen J., and Yu X. Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science (New York, N.Y.) 316 (2007) 1202-1205
22. Kim J.M., Parmar K., Huang M., Weinstock D.M., Ruit C.A., Kutok J.L., and D'Andrea A.D. Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. Developmental Cell 16 (2009) 314-320
23. Kitagaki J., Agama K.K., Pommier Y., Yang Y., and Weissman A.M. Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2. Mol. Cancer Ther. 7 (2008) 2445-2454
24. Kojima K., Konopleva M., Samudio I.J., Shikami M., Cabreira-Hansen M., McQueen T., Ruvolo V., Tsao T., Zeng Z., Vassilev L.T., and Andreeff M. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 106 (2005) 3150-3159
25. LaCasse E.C., Cherton-Horvat G.G., Hewitt K.E., Jerome L.J., Morris S.J., Kandimalla E.R., Yu D., Wang H., Wang W., Zhang R., Agrawal S., Gillard J.W., and Durkin J.P. Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin. Cancer Res. 12 (2006) 5231-5241
26. Li W.D., Wang M.J., Ding F., Yin D.L., and Liu Z.H. Cytotoxic effect of a non-peptidic small molecular inhibitor of the p53-HDM2 interaction on tumor cells. World J. Gastroenterol. 11 (2005) 2927-2931
27. Liu Y., Lashuel H.A., Choi S., Xing X., Case A., Ni J., Yeh L.A., Cuny G.D., Stein R.L., and Lansbury Jr. P.T. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem. Biol. 10 (2003) 837-846
28. Maddika S., and Chen J. Protein kinase DYRK2 is a scaffold that facilitates assembly of an E3 ligase. Nat. Cell Biol. 11 (2009) 409-419
29. Maddika, S., Sy, S.M., Chen, J., 2009. Functional interaction between Chfr and Kif22 controls genomic stability. The Journal of biological chemistry.
30. Massoumi R., Chmielarska K., Hennecke K., Pfeifer A., and Fassler R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 125 (2006) 665-677
31. Mukhopadhyay D., and Riezman H. Proteasome-independent functions of ubiquitin in endocytosis and signaling. Science (New York, N.Y.) 315 (2007) 201-205
32. Mullally J.E., and Fitzpatrick F.A. Pharmacophore model for novel inhibitors of ubiquitin isopeptidases that induce p53-independent cell death. Mol. Pharmacol. 62 (2002) 351-358
33. Mullally J.E., Moos P.J., Edes K., and Fitzpatrick F.A. Cyclopentenone prostaglandins of the J series inhibit the ubiquitin isopeptidase activity of the proteasome pathway. J. Biol. Chem. 276 (2001) 30366-30373
34. Nakayama K.I., and Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat. Rev. 6 (2006) 369-381
35. Nalepa G., Rolfe M., and Harper J.W. Drug discovery in the ubiquitin-proteasome system. Nat. Rev. Drug Discov. 5 (2006) 596-613
36. Nickeleit I., Zender S., Sasse F., Geffers R., Brandes G., Sorensen I., Steinmetz H., Kubicka S., Carlomagno T., Menche D., Gutgemann I., Buer J., Gossler A., Manns M.P., Kalesse M., Frank R., and Malek N.P. Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition. Cancer Cell 14 (2008) 23-35
37. Nijman S.M., Luna-Vargas M.P., Velds A., Brummelkamp T.R., Dirac A.M., Sixma T.K., and Bernards R. A genomic and functional inventory of deubiquitinating enzymes. Cell 123 (2005) 773-786
38. Oliveira A.M., Chou M.M., Perez-Atayde A.R., and Rosenberg A.E. Aneurysmal bone cyst: a neoplasm driven by upregulation of the USP6 oncogene. J. Clin. Oncol. 24 (2006) e1; author reply e2
39. Ostrowska H. The ubiquitin-proteasome system: a novel target for anticancer and anti-inflammatory drug research. Cell Mol. Biol. Lett. 13 (2008) 353-365
40. Pickart C.M. Ubiquitin in chains. Trends Biochem. Sci. 25 (2000) 544-548
41. Pickart C.M., and Eddins M.J. Ubiquitin: structures, functions, mechanisms. Biochim. Biophys. Acta 1695 (2004) 55-72
42. Piva R., Ruggeri B., Williams M., Costa G., Tamagno I., Ferrero D., Giai V., Coscia M., Peola S., Massaia M., Pezzoni G., Allievi C., Pescalli N., Cassin M., di Giovine S., Nicoli P., de Feudis P., Strepponi I., Roato I., Ferracini R., Bussolati B., Camussi G., Jones-Bolin S., Hunter K., Zhao H., Neri A., Palumbo A., Berkers C., Ovaa H., Bernareggi A., and Inghirami G. CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 111 (2008) 2765-2775
43. Priolo C., Tang D., Brahamandan M., Benassi B., Sicinska E., Ogino S., Farsetti A., Porrello A., Finn S., Zimmermann J., Febbo P., and Loda M. The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Res. 66 (2006) 8625-8632
44. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., Rajkumar S.V., Srkalovic G., Alsina M., Alexanian R., Siegel D., Orlowski R.Z., Kuter D., Limentani S.A., Lee S., Hideshima T., Esseltine D.L., Kauffman M., Adams J., Schenkein D.P., and Anderson K.C. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348 (2003) 2609-2617
45. Saha A., and Deshaies R.J. Multimodal activation of the ubiquitin ligase SCF by Nedd8 conjugation. Mol. Cell 32 (2008) 21-31
46. Sakamoto K.M., Kim K.B., Verma R., Ransick A., Stein B., Crews C.M., and Deshaies R.J. Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation. Mol. Cell. Proteomics 2 (2003) 1350-1358
47. Sasiela C.A., Stewart D.H., Kitagaki J., Safiran Y.J., Yang Y., Weissman A.M., Oberoi P., Davydov I.V., Goncharova E., Beutler J.A., McMahon J.B., and O'Keefe B.R. Identification of inhibitors for MDM2 ubiquitin ligase activity from natural product extracts by a novel high-throughput electrochemiluminescent screen. J. Biomol. Screen. 13 (2008) 229-237
48. Secchiero P., Barbarotto E., Tiribelli M., Zerbinati C., di Iasio M.G., Gonelli A., Cavazzini F., Campioni D., Fanin R., Cuneo A., and Zauli G. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 107 (2006) 4122-4129
49. Soucy T.A., Smith P.G., Milhollen M.A., Berger A.J., Gavin J.M., Adhikari S., Brownell J.E., Burke K.E., Cardin D.P., Critchley S., Cullis C.A., Doucette A., Garnsey J.J., Gaulin J.L., Gershman R.E., Lublinsky A.R., McDonald A., Mizutani H., Narayanan U., Olhava E.J., Peluso S., Rezaei M., Sintchak M.D., Talreja T., Thomas M.P., Traore T., Vyskocil S., Weatherhead G.S., Yu J., Zhang J., Dick L.R., Claiborne C.F., Rolfe M., Bolen J.B., and Langston S.P. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458 (2009) 732-736
50. Stapnes C., Doskeland A.P., Hatfield K., Ersvaer E., Ryningen A., Lorens J.B., Gjertsen B.T., and Bruserud O. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. Br. J. Haematol. 136 (2007) 814-828
51. Stegmeier F., Rape M., Draviam V.M., Nalepa G., Sowa M.E., Ang X.L., McDonald III E.R., Li M.Z., Hannon G.J., Sorger P.K., Kirschner M.W., Harper J.W., and Elledge S.J. Anaphase initiation is regulated by antagonistic ubiquitination and deubiquitination activities. Nature 446 (2007) 876-881
52. Tamm I., Kornblau S.M., Segall H., Krajewski S., Welsh K., Kitada S., Scudiero D.A., Tudor G., Qui Y.H., Monks A., Andreeff M., and Reed J.C. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin. Cancer Res. 6 (2000) 1796-1803
53. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., and Liu E.A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (New York, N.Y.) 303 (2004) 844-848
54. Vaux D.L., and Silke J. IAPs, RINGs and ubiquitylation. Nat. Rev. Mol. Cell. Biol. 6 (2005) 287-297
55. Verma R., Peters N.R., D'Onofrio M., Tochtrop G.P., Sakamoto K.M., Varadan R., Zhang M., Coffino P., Fushman D., Deshaies R.J., and King R.W. Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain. Science (New York, N.Y.) 306 (2004) 117-120
56. Walden H., Podgorski M.S., and Schulman B.A. Insights into the ubiquitin transfer cascade from the structure of the activating enzyme for NEDD8. Nature 422 (2003) 330-334
57. Winston J.T., Strack P., Beer-Romero P., Chu C.Y., Elledge S.J., and Harper J.W. The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev. 13 (1999) 270-283
58. Yang Y., Ludwig R.L., Jensen J.P., Pierre S.A., Medaglia M.V., Davydov I.V., Safiran Y.J., Oberoi P., Kenten J.H., Phillips A.C., Weissman A.M., and Vousden K.H. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7 (2005) 547-559
59. Yang Y., Kitagaki J., Dai R.M., Tsai Y.C., Lorick K.L., Ludwig R.L., Pierre S.A., Jensen J.P., Davydov I.V., Oberoi P., Li C.C., Kenten J.H., Beutler J.A., Vousden K.H., and Weissman A.M. Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res. 67 (2007) 9472-9481
60. Yang Y., Kitagaki J., Wang H., Hou D.X., and Perantoni A.O. Targeting the ubiquitin-proteasome system for cancer therapy. Cancer Sci. 100 (2009) 24-28
61. Yaron A., Gonen H., Alkalay I., Hatzubai A., Jung S., Beyth S., Mercurio F., Manning A.M., Ciechanover A., and Ben-Neriah Y. Inhibition of NF-kappa-B cellular function via specific targeting of the I-kappa-B-ubiquitin ligase. Embo. J. 16 (1997) 6486-6494